Researchers showed that Sorafenib increased IL-15 production by FLT3-ITD leukemia cells, which in turn caused an increase in CD8+CD107a+IFN y T cells which eradicated leukemia in secondary recipients. This evidence concerns the gene LAMP1 and leukemia.